NDAINTRAVENOUSPOWDER
Approved
Jun 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pemetrexed Ditromethamine is an IV powder antimetabolite approved by Pfizer in June 2022 as a reformulation of the established pemetrexed franchise. The ditromethamine salt formulation represents an alternative delivery mechanism for this antifolate agent used primarily in oncology indications. Specific therapeutic indications are not detailed in the dataset provided.
Peak
Product is in peak commercial stage with moderate competitive pressure (30/100), suggesting stable team sizing but potential vulnerability to market erosion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product currently shows zero linked job postings, indicating limited active hiring momentum despite peak lifecycle status. Roles on this team focus on defending market share in a competitive oncology space where formulation innovation and payer strategy drive value.
Brand ManagerMedical Science Liaison
Worked on PEMETREXED DITROMETHAMINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.